Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Oct 01, 2015 2:42pm
128 Views
Post# 24154320

RE:RE:for chicago on the ascam MB....

RE:RE:for chicago on the ascam MB....Hi Chicagoest.

I really can't see RVX hitting $2.67 given the steady stream of great news we've seen for almost 2 years. It seemed to me that the Hepalink deal was the key driver up to over $3.00 and then it has faded since.

The Yale Club presentation truly showcased the incredible scientific progress of this company and yet there has been no impact.

At the AGM when Don was asked about a NASDAQ listing for TVX he said "soon" (whatever soon means).

If I assume that "soon" is Q4 then he'll need to incredible tricks up his sleeve to put the stock at $2.67. 

The scientific progress at RVX has been nothing short of amazing (as evidenced at the Yale Club). I sure hope Don has not made another of his gaffs/false promises because it is him that causes the hesitancy in investor's. Trust is essential.

He's a smart man running a remarkable company so I sure would like to see that NASDAQ.

Toinv





Bullboard Posts